Xia Zengfei, Ou-Yang Wen, Hu Ting, Du Ketao
The Second Clinical Medical College, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
The Second Clinical Medical College, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Cancer Genet. 2019 Apr;233-234:67-74. doi: 10.1016/j.cancergen.2019.04.001. Epub 2019 Apr 9.
Cell division cycle 25C (CDC25C) is involved in the regulation of the G2/M phase transition and is associated with various cancers, including non-small cell lung cancer. We evaluated its prognostic value in lung adenocarcinoma (LUAD) based on data from The Cancer Genome Atlas (TCGA).
Kruskal-Wallis test, Wilcoxon signed-rank test, and logistic regression were used to evaluate relationships between clinical-pathologic features and CDC25C expression. Cox regression analyses and the Kaplan-Meier method were used to evaluate factors contributing to prognosis. Gene set enrichment analysis (GSEA) was performed.
High CDC25C expression in LUAD was associated with a high tumor extent (odds ratio (OR) = 2.23 (1.52-3.29), P < 0.001), regional lymph node invasion (OR = 2.18 (1.48-3.22), P < 0.001), OR = advanced stage (OR = 2.47 (1.72-3.59), P < 0.001), and poor status (OR = 1.87 (1.19-2.96), P = 0.007). A univariate analysis showed that high CDC25C expression is associated with a short overall survival (OS) (HR: 1.873; 95% CI: 1.385-2.535; P < 0.001) and poor progression-free survival (HR: 1.503; 95% CI: 1.173-1.926; P = 0.0012). In a multivariate analysis, high CDC25C expression was associated with poor OS (HR = 2.193; CI: 1.394-3.452, P = 0.001). GSEA showed the enrichment of cell cycle, apoptosis, p53-dependent G1 DNA damage response, S-phase, mitotic M-M G1 phases, and FA-mediated cell death in the CDC25C high-expression phenotype.
CDC25C predicts poor prognosis in LUAD and may function in cell cycle regulation and FAS-mediated apoptosis.
细胞分裂周期25C（CDC25C）参与G2/M期转换的调控，且与包括非小细胞肺癌在内的多种癌症相关。我们基于癌症基因组图谱（TCGA）的数据评估了其在肺腺癌（LUAD）中的预后价值。
采用Kruskal-Wallis检验、Wilcoxon符号秩检验和逻辑回归来评估临床病理特征与CDC25C表达之间的关系。采用Cox回归分析和Kaplan-Meier方法来评估影响预后的因素。进行基因集富集分析（GSEA）。
LUAD中高CDC25C表达与高肿瘤范围（优势比（OR）=2.23（1.52 - 3.29），P<0.001）、区域淋巴结侵犯（OR = 2.18（1.48 - 3.22），P<0.001）、晚期（OR = 2.47（1.72 - 3.59），P<0.001）及不良状态（OR = 1.87（1.19 - 2.96），P = 0.007）相关。单因素分析显示，高CDC25C表达与总生存期（OS）缩短（HR：1.873；95%置信区间：1.385 - 2.535；P<0.001）及无进展生存期差（HR：1.503；95%置信区间：1.173 - 1.926；P = 0.0012）相关。多因素分析中，高CDC25C表达与不良OS相关（HR = 2.193；置信区间：1.394 - 3.452，P = 0.001）。GSEA显示细胞周期、凋亡、p53依赖的G1期DNA损伤反应、S期、有丝分裂M - M G1期及FA介导的细胞死亡在CDC25C高表达表型中富集。
CDC25C预测LUAD预后不良，可能在细胞周期调控和FAS介导的凋亡中发挥作用。
